ChiCTR2600120879 版本V1.0 版本创建时间2026/03/20 17:18:46 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600120879 

最近更新日期:

Date of Last Refreshed on:

2026-03-20 17:18:39 

注册时间:

Date of Registration:

2026-03-20 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

儿童股骨头缺血性坏死非手术治疗的管理强度差异及其疗效分析——基于系统综述与单中心回顾性队列研究

Public title:

Analysis of Differences in Management Intensity and Efficacy of Non-surgical Treatment for Pediatric Avascular Necrosis of the Femoral Head: Based on a Systematic Review and a Single-center Retrospective Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

儿童股骨头缺血性坏死非手术治疗的管理强度差异及其疗效分析——基于系统综述与单中心回顾性队列研究

Scientific title:

Analysis of Differences in Management Intensity and Efficacy of Non-surgical Treatment for Pediatric Avascular Necrosis of the Femoral Head: Based on a Systematic Review and a Single-center Retrospective Cohort Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李子祺 

研究负责人:

李子祺 

Applicant:

Li Ziqi 

Study leader:

Li Ziqi 

申请注册联系人电话:

Applicant telephone:

+86 20 2229 2983

研究负责人电话:

Study leader's
telephone:

+86 20 2229 2983

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ionsev0214@126.com

研究负责人电子邮件:

Study leader's E-mail:

ionsev0214@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市荔湾区龙溪大道261-263号

研究负责人通讯地址:

广东省广州市荔湾区龙溪大道261-263号

Applicant address:

No. 261–263 Longxi Avenue, Liwan District, Guangzhou, Guangdong Province

Study leader's address:

No.261-263, Longxi Avenue, Liwan District, Guangzhou City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学第三附属医院

Applicant's institution:

The Third Affiliated Hospital of Guangzhou University of Chinese Medicine

研究负责人所在单位:

广州中医药大学第三附属医院

Affiliation of the Leader:

The Third Affiliated Hospital of Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

PJ-XS-20251023-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州中医药大学第三附属医院医学伦理委员会

Name of the ethic committee:

The Medical Ethics Committee of the Third Affiliated Hospital of Guangzhou University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-23 00:00:00

伦理委员会联系人:

简焕玲

Contact Name of the ethic committee:

Jian Huanling

伦理委员会联系地址:

广东省广州市荔湾区龙溪大道261-263号

Contact Address of the ethic committee:

No.261-263, Longxi Avenue, Liwan District, Guangzhou City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 22292571

伦理委员会联系人邮箱:

Contact email of the ethic committee:

543610903@qq.com

研究实施负责(组长)单位:

广州中医药大学第三附属医院

Primary sponsor:

The Third Affiliated Hospital of Guangzhou University of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市荔湾区龙溪大道261-263号

Primary sponsor's address:

No.261-263, Longxi Avenue, Liwan District, Guangzhou City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第三附属医院

具体地址:

广东省广州市荔湾区龙溪大道261-263号

Institution
hospital:

The Third Affiliated Hospital of Guangzhou University of Chinese Medicine

Address:

No.261-263, Longxi Avenue, Liwan District, Guangzhou City, Guangdong Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected Project (Self-funded)

研究疾病:

儿童股骨头缺血性坏死  

Target disease:

Legg–Calvé–Perthes Disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

主要目的:比较不同管理强度下非手术治疗 LCPD 的长期疗效(以 Stulberg 分型Ⅰ–Ⅱ 比例为主要指标)。 次要目的: 1.探讨管理强度在不同年龄组(<6 岁、6–<8 岁、>=8 岁)患儿中的适用性。 2.分析影响非手术疗效的独立危险因素(如年龄、Herring 分型)。 3.验证单中心严格管理模式与既往文献结果的差异。  

Objectives of Study:

Primary objective: To compare the long-term efficacy of non-surgical treatment of LCPD under different management intensities (using the proportion of Stulberg classification I–II as the main indicator). Secondary objectives: 1. To explore the applicability of management intensity in children of different age groups (<6 years, 6–<8 years, >=8 years). 2. To analyze independent risk factors affecting the non-surgical efficacy (such as age, Herring classification). 3. To verify the differences between the results of a single-center strict management model and those reported in previous literature.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合 LCPD 的临床及影像学诊断标准;
2.全程接受非手术治疗;
3.有完整的影像学及结局资料;

Inclusion criteria

1.Meeting the clinical and radiographic diagnostic criteria for Legg–Calvé–Perthes disease (LCPD);
2.Receiving nonoperative treatment throughout the entire course of the disease;
3.Having complete radiographic and outcome data.

排除标准:

1.病程中合并继发性髋关节炎或其他髋关节疾病;
2.既往接受过髋关节相关手术治疗;
3.影像学或病历资料缺失,无法进行疗效评估;

Exclusion criteria:

1.Presence of secondary hip arthritis or other concomitant hip disorders during the disease course;
2.History of previous hip-related surgical intervention;
3.Incomplete radiographic or clinical records precluding outcome evaluation;

研究实施时间:

Study execute time:

From 2025-12-01 00:00:00 To 2026-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-01 00:00:00 To 2026-12-01 00:00:00

干预措施:

Interventions:

组别:

石膏外展固定组

样本量:

399

Group:

Prolonged Abduction Containment Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第三附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

Waldenstr?m 分期

指标类型:

次要指标

Outcome:

Waldenstr?m staging

Type:

Secondary indicator

测量时间点:

每三月随访时

测量方法:

Measure time point of outcome:

At each three-month follow-up

Measure method:

指标中文名:

Stulberg 分型

指标类型:

主要指标

Outcome:

Stulberg classification

Type:

Primary indicator

测量时间点:

每三月随访时

测量方法:

Measure time point of outcome:

At each three-month follow-up

Measure method:

指标中文名:

Herring分型

指标类型:

次要指标

Outcome:

Herring classification

Type:

Secondary indicator

测量时间点:

每三月随访时

测量方法:

Measure time point of outcome:

At each three-month follow-up

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

no

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

国家生物信息中心(https:/ngdc.cncb.ac.cn/gsub/) 预计共享时间2026年12月1日

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

China National center for Bioinformation (https:/ngdc.cncb.ac.cn/gsub/)Expected Sharing Date: December 1, 2026

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究的数据来源于我院医学影像系统及电子病历系统,研究者按既定标准收集LCPD患儿的临床与影像学资料(包括年龄、性别、Waldenstr?m分期、Herring分型、Catterall分型、治疗方式及Stulberg结局)。所有数据均在院内安全网络中采集与管理,使用唯一编号进行去标识化处理,仅研究团队成员可访问,未经许可不外传。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data for this study will be obtained from the hospital’s medical imaging and electronic medical record systems. Researchers will collect clinical and radiographic information of LCPD patients according to predefined criteria, including age, sex, Waldenstr?m stage, Herring classification, Catterall classification, treatment method, and Stulberg outcome. All data will be collected and managed within the hospital’s secure network, anonymized using unique identifiers, and accessible only to the study team.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-03-20 17:18:39